These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 24683046)

  • 1. Darbepoetin for the anaemia of chronic kidney disease.
    Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Chung EY; Palmer SC; Saglimbene VM; Craig JC; Tonelli M; Strippoli GF
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD010590. PubMed ID: 36791280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
    Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
    Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
    J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
    Alsalimy N; Awaisu A
    Int J Clin Pharm; 2014 Dec; 36(6):1115-25. PubMed ID: 25288147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
    Hahn D; Cody JD; Hodson EM
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.
    Carrera F; Lok CE; de Francisco A; Locatelli F; Mann JF; Canaud B; Kerr PG; Macdougall IC; Besarab A; Villa G; Kazes I; Van Vlem B; Jolly S; Beyer U; Dougherty FC;
    Nephrol Dial Transplant; 2010 Dec; 25(12):4009-17. PubMed ID: 20522670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
    Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
    Locatelli F; Hannedouche T; Fishbane S; Morgan Z; Oguey D; White WB
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1701-1710. PubMed ID: 31420350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
    Hörl WH
    Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.
    Curran MP; McCormack PL
    Drugs; 2008; 68(8):1139-56. PubMed ID: 18484803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study.
    Gobin J; Cernii A; McLean R; Finkelstein FO; Simon DB
    Clin Drug Investig; 2011; 31(2):113-20. PubMed ID: 21067252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral versus oral iron therapy for adults and children with chronic kidney disease.
    O'Lone EL; Hodson EM; Nistor I; Bolignano D; Webster AC; Craig JC
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD007857. PubMed ID: 30790278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.